Sign in
KLTO Stock Price, Chart, Stats & News
Klotho Neurosciences, Inc.
Save
20.08M
Market cap
–
Current P/E
–
Forward P/E
KLTO chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -112.08% |
ROE | -201.59% |
D/E | – |
Interest coverage ratio | -1.90x |
KLTO valuation
P/E | – |
P/S | – |
P/B | 2.28x |
P/CF | -4.08x |
P/FCF | -3.62x |
P/OCF | -4.08x |
PEG | -0.07x |
EV multiple | -3.66x |
About
Klotho Neurosciences, Inc. operates as a biopharmaceutical enterprise focused on devising medical treatments for various conditions, including cancer, cardiovascular ailments, and neurodegenerative disorders. Their leading gene therapy assets encompass AMI-101, which is designed for the management or prevention of Alzheimer's disease, and AMI-202, aimed at treating or averting amyotrophic lateral sclerosis. Formerly known as Anew Medical, Inc., the company underwent a name change to Klotho Neurosciences, Inc. in September 2024.
Similar securities
Based on sector and market capitalization
Report issue